Castleark Management LLC Arvinas, Inc. Transaction History

Castleark Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $197,179 - $283,520	5,420 Added 7.57%	76,990 $3.18 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $1.02 Million - $3.03 Million	71,570 New	71,570 $2.95 Million
Q3 2022 Nov 15, 2022	BUY	$41.87 - $57.99 $1.8 Million - $2.49 Million	42,890 New	42,890 $1.91 Million
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $2.09 Million - $2.83 Million	-34,730 Closed	0 $0
Q4 2021 Feb 16, 2022	SELL	$65.85 - $96.21 $2.77 Million - $4.05 Million	-42,085 Reduced 54.79%	34,730 $2.85 Million
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $1.75 Million - $2.58 Million	23,885 Added 45.13%	76,815 $6.31 Million
Q2 2021 Aug 17, 2021	BUY	$60.45 - $84.26 $3.2 Million - $4.46 Million	52,930 New	52,930 $4.08 Million
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $978,420 - $1.86 Million	-32,745 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$33.0 - $54.5 $1.08 Million - $1.78 Million	32,745 New	32,745 $1.32 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.